+ Science & politics – synergy or conflict The drive to time-limit OST – is it austerity or ideology ? Is it good science and good practice ? Annette Dale-Perera.

Slides:



Advertisements
Similar presentations
NTA Residential Rehabilitation Event Welcome Baroness Massey of Darwen.
Advertisements

Building Recovery: The role of Payment by Results Marcus Roberts Director of Policy and Membership, DrugScope.
Recovery led Drugs Policy – Employment and Welfare Reform Neil Hodgson 20 July 2010.
Hayden Duncan Regional Manager National Treatment Agency 1 for Substance Misuse.
Options appraisal, the business case & procurement
London, Drugs and You – the Role of Elected Members May 11th 2009 Facilitated by David MacKintosh and Sara McGrail.
Anna Whalen Youth Homelessness Advisor. 1. Minimise Demand: Education work in schools /other places on reality of housing choices 2. Reduce Demand & Crisis.
Tobacco control and the new structures for public health Professor Kevin Fenton Director of Health & Wellbeing Twitter:
Suicide Prevention – a partnership approach Mark Smith Head of Suicide Prevention and Mental Health.
 Centre for Drug Misuse Research Glasgow Scotland From Harm Reduction to Abstinence: A Journey in Drug Treatment Pol From Harm Reduction to Abstinence:
John Marsden National Addiction Centre, London EMCDDA conference Lisbon 7 th May 2009.
Mark Allman: Vice Chair. Building on existing guides produced by cCLOA -Adult Social care -Crime and anti social behaviour Developed through wide stakeholder.
Adults and Communities Overview and Scrutiny Panel The Safer Doncaster Partnership (including an update on metal theft) 25 th June 2012.
The West Cheshire Way Be part of the conversation.. Alison Lee Chief Officer West Cheshire Clinical Commissioning Group Making sure you get the healthcare.
NHS finances – Demands and Challenges! Or Cause and Effect In Hospital Pharmacy Procurement Ian Bourns Director of Medicines Management and Pharmacy East.
NAT Roundtable 14/1/13 Pete Burkinshaw THE NEW COMMISSIONING ARRANGEMENTS FOR DRUG TREATMENT IN ENGLAND.
Hannah Lindsell Public Health England MEDICATIONS IN RECOVERY: RE-ORIENTATING DRUG DEPENDENCE TREATMENT HOW CAN WE MAKE SHARED-CARE IN WANDSWORTH MORE.
JOINING THE DOTS Connecting schools, voluntary and community sector and commissioning for better outcomes in emotional health and wellbeing.
Role The NHS new treatment landscape Annette Dale-Perera Strategic Director of Addictions and Offender Care CNWL NHS Foundation Trust.
Workforce development in the new Annette Dale- Perera Strategic Director of Addiction and Offender Care.
Public Health and Healthy Local Government Maggi Morris Executive Director of Public Health Central Lancashire.
Progress Through Partnership Improving Health Dr Yvonne Arthurs Deputy Regional Director of Public Health in South East Public Health Group.
The Opioid Replacement Therapies Review: an overview Dr Brian Kidd Chair Drug Strategy Delivery Commission.
School for Health Public Health Policy: The Issues, The Future Professor David Hunter.
Tabor Lodge Addiction and Housing Services Limited Cork.
Substitute Prescribing Paul Smith BS.c Addiction Counselling.
CENTRE FOR INCLUSION AND CITIZENSHIP TIM STAINTON CENTRE FOR INCLUSION AND CITIZENSHIP UNIVERSITY OF BRITISH COLUMBIA Lessons from the global experience.
Supporting and investing in Camden’s voluntary and community sector (VCS) Proposed investment and support programme.
Commissioning for Culture, Health and Wellbeing Ian Tearle Head of Health Policy Directorate of Public Health, NHS Devon Wednesday 7 th March 2012.
An EMCDDA view on recovery Roland Simon Head of Unit Intervention, Best Practice, and Scientific Partners.
How can local initiatives help workless people find and keep paid work? Pamela Meadows Synergy Research and Consulting Ltd and National Institute of Economic.
Somerset health and wellbeing in learning programme Promoting healthy outcomes for children and young people through education Teresa Day – Health and.
PUBLIC HEALTH IN THE COUNCIL Judith Mills Public Health Specialist 18 th July 2013 Health Scrutiny Committee.
Tobacco harm reduction: NICE guidance and recent developments Linda Bauld.
PUBLIC HEALTH WORKFORCE LINCOLNSHIRE GOVERNMENT Isabel Perez, Consultant in Public Health 17 th June 2014.
Healthcare plays an important though proportionately small role in preventing early deaths. Improving how we live our lives offers far greater.
Early Help Strategy Achieving better outcomes for children, young people and families, by developing family resilience and intervening early when help.
Rediscovering Recovery: A Revolution in UK Drug Treatment Policy Neil McKeganey Professor of Drug Misuse Research University of Glasgow.
GRAND Getting Real about Alcohol ‘N’ Drugs Community responses to alcohol and drug issues ADP Communities Sub-group Presentation to Community Council’s.
Alcohol strategies: chances for change Emily Robinson Deputy Chief Executive Alcohol Concern.
Criteria for Assessing The Feasibility of RCTs. RCTs in Social Science: York September 2006 Today’s Headlines: “Drugs education is not working” “ having.
Reverse Commissioning An Effective Process to Engage BME Communities Dr Vivienne Lyfar-Cissé MBA Chair NHS BME Network.
Dundee Partnership Community Conference 17 th September 2011 What are we trying to achieve? The national picture Dr Brian Kidd – NHS Tayside.
The New Mental Health Strategy for England Dr Hugh Griffiths National Clinical Director for Mental Health.
1 The Policy Making Process and the Positive Ageing Strategy Eileen Kehoe Office for Older People Department of Health and Children.
Criminal Justice Intervention Team First contact for adult offenders with drug/alcohol issues. Drug/Alcohol Arrest Referral Service South Gloucestershire.
Penny Emerit Acting Director of London Programmes May 2010 Polysystems: how do they support tackling health inequalities in Sectors and PCTs?
Social work and substance use policy Dr Sarah Galvani University of Bedfordshire Chair, BASW SIG in Alcohol and other Drugs.
Mary Manning, Executive Director. Getting started The Academy of Medical Sciences: who we are Getting started on policy work Governance Selecting topics.
NHS England New Structure and Industry Engagement Richard Stubbs Head of Commercial and International Innovation NHS England.
Commissioning Update – Specifications, Performance and Funding Ben Seale January 2012.
The future of the consortium William Butler Chair Substance Misuse Skills Consortium.
04/06/2016Presentation name104/06/2016Presentation name1 Adult Drug Misuse Kerry Anderson – Modernisation Manager, Public Health.
Innovating out of the recession in the NHS Steve Barnett, Chief Executive NHS Confederation 28 th October 2009 Foundation Trust Network - Primary Care.
A Vision for Adult Social Care: Capable Communities and Active Citizens The Coalition Government’s approach to future reform of adult social care.
The Opioid Replacement Therapies Review: Dr Kennedy Roberts Lead Researcher, ORT Review Scottish Prison Service College Polmont 20 th. March 2015.
Housing, Homelessness and Substance Misuse Recommendations from the Advisory Group.
The Effects of National Legislation on the Public Health Role of Local Government in England Oslo, December 2015 Professor John Kenneth Davies Centre for.
Mental Health Commissioning in Tower Hamlets 15 th October 2015.
Focus on Addictions and Homelessness Catriona Ritchie NHSGGC Addictions Services GP ST 1+2 Teaching – Deprivation Related Problems in General Practice.
NTA, 20/11/2012 MEDICATIONS IN RECOVERY: RE-ORIENTATING DRUG DEPENDENCE TREATMENT Report of the Recovery Orientated Drug Treatment Expert Group.
1 Maintaining downward pressure on smoking prevalence Robert West University College London All Party Parliamentary Group on Smoking September 2015.
Community Health Champions in Sheffield – the story so far! Real change can only come from the local community itself by harnessing the energy, skills.
Reforming the State System for the provision of social services, setting the vision, aims and objectives: The United Kingdom Experience Mr Sean Holland.
Overview and Scrutiny, Coordinating and Call In Committee Personalisation Presentation 3 March 2009.
Commissioning for Wellbeing Time banking and other initiatives in Plymouth Rachel Silcock.
The Role of the Work and Health Unit and Engagement All Party Group on Health & Work 25 May 2016 Deborah Jamieson, OBE Work and Health Unit.
North Somerset Partnership Priorities & Opportunities 2 December 2015.
Karen Creavin Head of Birmingham Wellbeing Services
Hannah Lindsell Public Health England
Presentation transcript:

+ Science & politics – synergy or conflict The drive to time-limit OST – is it austerity or ideology ? Is it good science and good practice ? Annette Dale-Perera

+ Declaration of interests & conflicts 2015 Independent consultancy company: contracts with Home Office, CRI, Labour Party, Responsible Gambling Trust, Inspire Education, etc. Director Choices Consortium CIC; Trustee Adfam and Build on Belief Member of Advisory Council of the Misuse of Drugs (ACMD) & co-chair of Recovery Committee Previously Director of NHS Addiction and Offender Health Services, Director of Quality National Treatment Agency for Substance Misuse; UKDPC; DrugScope, Research Fellow at Centre for Research on Drugs and Health behaviour, etc Speaking in independent capacity Yes, I am often conflicted about many things !

+ Time-limit OST: OST ‘cure to curse’ rapid expansion of drug treatment in England Pre 2008: OST seen as positive, excellent drug treatment coverage 2007/8: ‘Broken Britain’ & ‘Addicted Britain’ Tory think tank Growing user/ ex-user lobby for healthier & more fulfilling lives; Some academics highlight poor quality drug treatment and an ‘ill’ marginalised population on OST 2010: new Government, new Drug Strategy. RECOVERY at its heart is POSITIVE but drive is for ABSTINENCE. OST seen as negative. Coalition government ‘special advisors’

+ Policy shift on OST – an analogy Choluteca Bridge: Honduras OST as a strong bridge to recovery

+ Choluteca Bridge Honduras after Hurricane Mitch OST stranding people in ill health isolation and unemployment

+ A Perfect Drug Policy Hurricane: austerity, Politics, ideology, competitive treatment market International Monetary Fund Public spending projections: UK below USA by 2017 Competitive market & re-procurement in England: An(other) English disease New Political ideology Government ideology is to reduce state dependence Heroin users in OST typify dependence on the state Conflict in Drug Treatment Recovery revolution: like a ‘class war’- some user groups Tensions harm reduction, social asset building approach, & ‘medical management’ Evidence is we need ALL for recovery-orientated treatment Austerity Real risks to more expensive treatments, staff, and quality due to reduced budgets

+ Fuelled by competing voices in our field Recovery is an individual process involving: overcoming dependence; maximising health and wellbeing and people being participating members of society Recovery is social revolution for drug users who suffer health inequalities ‘The only True Recovery is abstinence’ Full Recovery (Abstinence) is the only recovery we will accept Reduction of harm alone is not an acceptable outcome Medical management of substance addiction without asset building leads to people being parked on methadone The drive for recovery was positive but fell into BLAME CULTURE around types of treatment and recovery interventions and services users. Stories vs research

+ Managing the politics of recovery Inter-ministerial Group on Drugs: IMG Coalition government politics plus departmental interests. Challenge - lack of ambition, “poor outcomes” & OST system failure ACMD Recovery Committee created to provide evidence-based advice to ministers due to ‘conflicting voices’ about Recovery NTA changed key performance indicators to treatment completion without re-presentation Drug Advisors from USA including Keith Humphries & Thom McLellan Professor John Strang recovery - - orientated expert group reports (SOME) MINISTERS CONTINUED TO BE UNHAPPY ABOUT OST

+ ACMD RC was given the question …… Does evidence supports the case for time-limiting opioid substitution therapy (OST); and if so, what would be a suitable time period and what would the risks and benefits be? Part 1 Additionally, if this is not the case how can continuing opioid substitution therapy be optimised in order to maximise service user outcomes ? Part 2 Part 1 delivered Nov 2014 Part 2 delivered June 2015 and Oct 2015

+ Answer to time-limiting OST: Part 1 Evidence does not support a blanket policy to time-limit OST The likely result would be relapse with significant unintended consequences including: Increased crime (drug Tx = 25-33% of fall in acquisitive crime), increase in BBV and drug-related death. Medico-legal challenges may make it un-implementable Most are not ‘parked’. Most have episodic use of OST % have been in OST 5 yrs or more. 40% retained less than 6 months, median stay is around 300 days, 69% in OST under 2 yrs BUT: there are significant issues around variable quality drug treatment and recovery systems.

+ REACTION

+ IMG reactions to Part 1 Chair: Norman Baker LibDem had just resigned over Tory’s non evidence-based approach to drug policy Most departments accepted the report, some reluctantly Some did NOT accept the report Ian Duncan Smith DWP complained about ACMD and wrote personal letter to Daily Telegraph … we must now fight the Methadone Industry that keeps addicts hooked… The Home Office control the drug strategy MORE QUESTIONS FOR OST PART 2

+ Part 2: Optimising OST key messages We cannot tell who will ‘get better’ except broad predictors Protect the investment – it is at risk Strive for stability in drug treatment so stop frequent re- procurement which has a negative impact on recovery outcomes National improvement programme for OST to ensure evidence- based practice is implemented. Set clear minimum standards Ensure enough abstinence pathways & ongoing recovery support Tackle discrimination and stigmatising of those in medication assisted recovery by health services; employers and communities More research to build UK evidence on recovery

+ Conclusions DRUG TREATMENT in UK is always driven by ideology New drug strategy is due There has been a fundamental shift in belief about ‘what works’ Resource cuts and drive for cheapest is mitigating against evidence- based practice and ‘expensive staff’/interventions. WE NEED TO KEEP DELIVERING EVIDENCE-BASED ADVICE WE NEED MORE EVIDENCE TO TRACK IMPACT OF TRENDS IN COMMISSIONING, CHANGES IN PROVISION & RESOURCE CUTS ON RECOVERY OUTCOMES A ROLE FOR SSA AND RESEARCH. PLEASE HELP. Don’t leave it to ACMD volunteers with no budget and ‘official statistics’